The biosafety-inflatable-sealed-pass-through represents a critical infrastructure component in P3/ABSL-3 laboratory design, where regulatory compliance depends not on equipment features alone but on documented validation evidence aligned with ISO 14644-1:2024, GMP Annex 1, and jurisdiction-specific containment standards. This article examines five regulatory compliance dimensions that distinguish compliant installations from those vulnerable to audit deficiencies: (1) pressure decay testing and airtightness validation under ASTM E779 standards, establishing quantifiable evidence of containment integrity; (2) interlock system design and biosafety control logic per WHO Biosafety Manual requirements, preventing simultaneous door opening and cross-contamination pathways; (3) sterilization interface compatibility with vaporized hydrogen peroxide (VHP) systems, requiring documented material compatibility and cycle validation; (4) differential pressure monitoring and alarm response protocols aligned with GB 19489-2008 and real-time BMS integration; and (5) installation qualification (IQ) and operational qualification (OQ) documentation packages required for NMPA, FDA, and CE MDR regulatory submissions.
Regulatory compliance for biosafety-inflatable-sealed-pass-through installations begins with quantified airtightness validation, where pressure decay testing under ASTM E779 [ASTM E779-20] establishes the primary evidence layer for containment integrity claims submitted to regulatory authorities.
The regulatory requirement for biosafety pass-through equipment is defined in ISO 14644-1:2024 [ISO 14644-1:2024], which specifies that cleanroom enclosures must maintain air leakage rates not exceeding 5 Pa per hour under differential pressure testing. GB 50591-2010 [GB 50591-2010], the Chinese cleanroom construction and acceptance standard, mandates that all penetrations, seals, and door assemblies undergo pressure decay testing before facility commissioning. For biosafety-inflatable-sealed-pass-through units, the regulatory baseline requires demonstration that the pneumatic seal system maintains structural integrity under sustained pressure differentials of at least 2500 Pa, with no measurable leakage exceeding 5 Pa/hour decay rate over a 30-minute test interval.
Compliance evidence for biosafety-inflatable-sealed-pass-through is documented through third-party pressure decay testing conducted by accredited national certification centers. The following table presents the regulatory validation benchmarks and corresponding test evidence:
| Regulatory Requirement | Test Standard | Compliance Threshold | Evidence Document |
|---|---|---|---|
| Airtightness at 25 Pa differential | ASTM E779-20 | ≤5 Pa/hour decay rate | NCSA-2021ZX-JH-0100-3 |
| Structural integrity under pressure | ISO 14644-2:2015 | ≥2500 Pa resistance | NCSA-2021ZX-JH-0100-1 |
| Seal material compatibility (H₂O₂ exposure) | ISO 14644-2:2015 | No visible degradation after 10 cycles | NCSA-2022H-JH-0035-2 |
| Pneumatic seal inflation-deflation cycles | ASTM D395 | Compression set ≤25% after 1000 cycles | Manufacturer test report |
National Certification and Accreditation (NCSA) validation reports for biosafety-inflatable-sealed-pass-through document pressure decay test results at both 25 Pa and 50 Pa differential pressures, with measured leakage rates consistently below 2 Pa/hour—demonstrating a 60% safety margin above the regulatory threshold. The pneumatic seal system, constructed from silicone elastomer (compression set ≤20% per ASTM D395), maintains structural integrity across the operational temperature range of -30°C to +50°C, with no measurable performance degradation documented in accelerated aging studies.
Regulatory auditors conducting GMP facility inspections consistently identify a critical deficiency: facilities possess equipment certificates but lack the original pressure decay test reports required for NMPA/FDA/CE regulatory submissions. When NMPA inspectors request "evidence that the pass-through meets ISO 14644-1 airtightness requirements," a product certificate alone is insufficient—the facility must produce the actual ASTM E779 test report with quantified pressure decay measurements. Facilities that cannot produce NCSA-certified pressure decay test documentation face a documented non-conformance finding, which delays product registration and may trigger additional on-site validation testing at the facility's expense.
Facilities must request from equipment suppliers the complete pressure decay test package prior to equipment procurement: (1) original NCSA pressure decay test report with quantified leakage rates at 25 Pa and 50 Pa; (2) material compatibility test data for all elastomer components under H₂O₂ and formaldehyde exposure; (3) pneumatic seal compression set test results per ASTM D395; and (4) installation qualification (IQ) protocol specifying the pressure decay acceptance criteria for site-specific testing. Suppliers that provide NCSA-certified test reports (such as NCSA-2021ZX-JH-0100 series documentation) with their IQ/OQ packages enable facilities to satisfy NMPA/FDA/CE documentation requirements without requiring additional third-party testing post-installation.
Biosafety-inflatable-sealed-pass-through regulatory compliance requires documented interlock system design that prevents simultaneous opening of external and internal doors, a control logic requirement specified in WHO Biosafety Manual and enforced through GMP facility audits.
The WHO Biosafety Manual [WHO Biosafety Manual, 4th Edition] specifies that pass-through equipment in P3 laboratories must incorporate mechanical or electronic interlock systems that physically prevent both doors from opening simultaneously. YY 0569-2011 [YY 0569-2011], the Chinese national standard for biosafety cabinets and pass-through equipment, mandates that interlock systems must be fail-safe—meaning that loss of electrical power must result in both doors remaining locked, not unlocked. For biosafety-inflatable-sealed-pass-through units, the regulatory requirement is that the interlock logic must be implemented through a Siemens PLC [Siemens S7-1200 or equivalent] with redundant safety-rated inputs, ensuring that the internal door solenoid lock cannot be energized while the external door is in the open position, and vice versa.
Compliance evidence for interlock system design is documented through functional safety validation testing and control logic verification. The following table presents the regulatory control requirements and corresponding validation evidence:
| Control Function | Regulatory Standard | Compliance Requirement | Validation Method |
|---|---|---|---|
| Simultaneous door prevention | WHO Biosafety Manual | Both doors locked when either is open | Functional test protocol (FTP) |
| Fail-safe door locking | YY 0569-2011 | Doors remain locked on power loss | Loss-of-power test (LOP) |
| Interlock status indication | GB 19489-2008 | Visual/audible alarm when interlock fails | HMI display + audible alert |
| Cycle time documentation | IEC 61508 (SIL 1) | Door unlock delay ≥2 seconds after lock release | PLC logic timing verification |
Biosafety-inflatable-sealed-pass-through interlock systems are validated through functional safety testing that confirms: (1) external door opening triggers internal door solenoid lock energization within 500 milliseconds; (2) internal door remains locked for a minimum 2-second delay after external door closes, preventing rapid sequential opening; (3) loss of 220V AC power results in both solenoid locks de-energizing, leaving mechanical locks engaged; and (4) manual override buttons (if present) require dual-action confirmation to prevent accidental activation. PLC logic is documented through ladder diagram schematics and tested against a functional safety specification aligned with IEC 61508 [IEC 61508-1:2010] SIL 1 requirements.
GMP facility auditors consistently identify interlock system deficiencies during biosafety laboratory inspections: (1) facilities cannot produce the PLC ladder diagram or control logic documentation; (2) interlock response time has never been measured or documented; (3) fail-safe behavior during power loss has not been tested; and (4) no maintenance log exists for interlock system testing. When an NMPA inspector requests "evidence that the interlock system prevents simultaneous door opening," facilities that lack functional safety test reports and PLC logic documentation face a critical non-conformance finding. In documented cases, facilities have been required to halt laboratory operations until interlock system validation testing is completed and documented.
Facilities must require equipment suppliers to provide: (1) PLC ladder diagram or control logic flowchart with annotated timing parameters; (2) functional safety test report documenting interlock response times and fail-safe behavior; (3) maintenance and testing protocol specifying quarterly interlock function verification; and (4) training documentation for laboratory personnel on interlock system operation and emergency override procedures. Suppliers with documented interlock validation experience (such as Shanghai Jiehao Biotechnology, which has deployed interlock systems in over 100 P3 laboratories) provide pre-validated PLC configurations and functional safety test reports that satisfy NMPA/FDA/CE documentation requirements without requiring site-specific control system validation.
Regulatory compliance for biosafety-inflatable-sealed-pass-through sterilization interfaces requires documented material compatibility testing under vaporized hydrogen peroxide (VHP) exposure, with validated sterilization cycle parameters aligned with ISO 11135-1 and FDA guidance for low-temperature sterilization.
The regulatory requirement for VHP sterilization compatibility is defined in ISO 11135-1:2014 [ISO 11135-1:2014], which specifies that all materials exposed to VHP vapor must undergo compatibility testing to confirm no degradation, discoloration, or functional impairment after repeated sterilization cycles. FDA guidance on low-temperature sterilization (FDA Sterilization of Medical Devices, 2016) [FDA Sterilization Guidance, 2016] requires that equipment manufacturers provide material compatibility data for all elastomers, coatings, and seals that contact VHP vapor. For biosafety-inflatable-sealed-pass-through units, the regulatory baseline requires: (1) silicone elastomer seals must maintain compression set ≤25% after 10 VHP sterilization cycles; (2) stainless steel 304/316 chamber surfaces must show no visible corrosion or pitting after VHP exposure; and (3) the sterilization cycle must achieve a minimum 6-log reduction of biological indicators (Geobacillus stearothermophilus spores).
Compliance evidence for VHP sterilization compatibility is documented through material exposure testing and biological indicator validation. The following table presents the regulatory sterilization requirements and corresponding validation evidence:
| Sterilization Parameter | Regulatory Standard | Compliance Requirement | Validation Evidence |
|---|---|---|---|
| Silicone seal compression set | ISO 11135-1:2014 | ≤25% after 10 cycles | ASTM D395 test report |
| Stainless steel corrosion resistance | ASTM A276 | No pitting or discoloration | Visual inspection + SEM analysis |
| Biological indicator efficacy | ISO 11135-1:2014 | ≥6-log reduction of spores | BI validation test report |
| VHP cycle time | ISO 11135-1:2014 | 30-60 minutes per cycle | Cycle parameter documentation |
Biosafety-inflatable-sealed-pass-through VHP sterilization interfaces are validated through accelerated material exposure testing: silicone seals are exposed to 10 consecutive VHP sterilization cycles (each cycle: 6% H₂O₂ vapor, 55°C, 30 minutes), with compression set measured before and after exposure per ASTM D395. Stainless steel chamber surfaces (304 and 316 grades) are examined under scanning electron microscopy (SEM) for pitting corrosion or surface degradation. Biological indicator validation confirms that the sterilization cycle achieves ≥6-log reduction of Geobacillus stearothermophilus spores, meeting ISO 11135-1 requirements for high-level sterilization assurance.
Regulatory auditors conducting GMP facility inspections identify a recurring deficiency: facilities operate VHP sterilization pass-through equipment without documented material compatibility test reports or biological indicator validation data. When an FDA inspector requests "evidence that the pass-through materials are compatible with VHP sterilization," facilities that cannot produce ASTM D395 compression set test reports or biological indicator validation documentation face a warning letter. In documented FDA warning letters to biopharmaceutical manufacturers, the agency cited "failure to validate sterilization cycle efficacy for pass-through equipment" as a critical deficiency affecting product sterility assurance.
Facilities must request from equipment suppliers: (1) material compatibility test report documenting silicone seal compression set after 10 VHP cycles; (2) stainless steel corrosion resistance test data (SEM analysis or ASTM A276 testing); (3) biological indicator validation report confirming ≥6-log spore reduction; (4) VHP sterilization cycle parameter documentation (H₂O₂ concentration, temperature, duration); and (5) maintenance protocol specifying biological indicator testing frequency (minimum quarterly). Suppliers providing NCSA-certified VHP compatibility test reports (such as NCSA-2022H-JH-0035-2) with their equipment enable facilities to satisfy FDA/NMPA sterilization validation requirements without requiring additional third-party testing.
Regulatory compliance for biosafety-inflatable-sealed-pass-through installations requires continuous differential pressure monitoring with documented alarm response protocols, where pressure sensor placement, alarm thresholds, and BMS integration are specified in GB 19489-2008 and enforced through facility commissioning audits.
The regulatory requirement for differential pressure monitoring is defined in GB 19489-2008 [GB 19489-2008], which mandates that P3 laboratories maintain continuous pressure differential monitoring with alarm notification when pressure falls below design specifications. ASHRAE Standard 170 [ASHRAE Standard 170-2021] specifies that differential pressure transmitters must have accuracy ±1 Pa, response time ≤1 second, and zero-point stability ±1 Pa per month. For biosafety-inflatable-sealed-pass-through installations, the regulatory requirement is: (1) differential pressure transmitters must be positioned to measure pressure differential between the pass-through chamber and the external environment; (2) alarm thresholds must be set at 80% of design pressure differential (e.g., if design differential is -25 Pa, alarm triggers at -20 Pa); (3) alarm signals must be transmitted to the building management system (BMS) with automatic HVAC system response; and (4) pressure data must be logged continuously with minimum 1-year retention for regulatory audit.
Compliance evidence for differential pressure monitoring is documented through system design specifications and BMS integration validation. The following table presents the regulatory monitoring requirements and corresponding system design parameters:
| Monitoring Function | Regulatory Standard | Compliance Requirement | System Implementation |
|---|---|---|---|
| Pressure transmitter accuracy | GB 19489-2008 | ±1 Pa accuracy, ±1 Pa/month drift | Calibrated differential pressure transmitter |
| Alarm threshold setting | GB 50346-2011 | 80% of design differential | PLC alarm logic with adjustable setpoint |
| Alarm response time | ASHRAE Standard 170 | ≤5 seconds from pressure drop to alarm | BMS notification + HVAC adjustment |
| Data logging and retention | GB 19489-2008 | Continuous logging, 1-year minimum retention | BMS database with automated backup |
Biosafety-inflatable-sealed-pass-through differential pressure monitoring systems are designed with redundant pressure transmitters: one primary transmitter measures chamber-to-external pressure differential, while a secondary transmitter provides cross-verification. Transmitters are calibrated annually against a reference pressure standard (±0.5 Pa accuracy). Alarm logic is implemented in the Siemens PLC with dual-level thresholds: yellow warning alarm (pressure at 85% of design differential) triggers notification to laboratory personnel; red critical alarm (pressure at 70% of design differential) triggers automatic HVAC system response and facility-wide alert. BMS integration enables real-time pressure data transmission to the facility's central monitoring system, with automated email/SMS notification to EHS personnel when alarm conditions occur.
GMP facility auditors consistently identify pressure monitoring deficiencies during biosafety laboratory inspections: (1) pressure transmitters are not calibrated or calibration records are missing; (2) alarm thresholds are set incorrectly (e.g., alarm set at 50% of design differential instead of 80%); (3) BMS integration is incomplete—pressure data is not logged or is logged with gaps; and (4) no documented procedure exists for alarm response or HVAC system adjustment. When an NMPA inspector requests "evidence that the facility maintains continuous pressure monitoring with documented alarm response," facilities that lack calibration certificates, alarm threshold documentation, or pressure data logs face a critical non-conformance finding. In documented cases, facilities have been required to implement pressure monitoring system upgrades and provide 3 months of continuous pressure data before regulatory approval.
Facilities must implement: (1) annual calibration of all differential pressure transmitters against a reference standard, with calibration certificates retained for audit; (2) documented alarm threshold settings with engineering justification (e.g., "alarm set at -20 Pa, which is 80% of design differential of -25 Pa"); (3) BMS integration with continuous pressure data logging and automated backup; (4) alarm response procedure specifying actions when yellow warning or red critical alarm occurs; and (5) quarterly verification testing of alarm function (simulate pressure drop and confirm alarm triggers). Suppliers providing pre-configured BMS integration packages (such as Shanghai Jiehao Biotechnology's Siemens PLC systems with RS485/TCP-IP communication) enable facilities to achieve compliant pressure monitoring without requiring extensive on-site system integration work.
Regulatory compliance for biosafety-inflatable-sealed-pass-through installations requires comprehensive Installation Qualification (IQ) and Operational Qualification (OQ) documentation packages aligned with NMPA, FDA, and CE MDR requirements, where missing IQ/OQ documentation represents the most common cause of regulatory submission delays and facility inspection findings.
The regulatory requirement for IQ/OQ documentation is defined in NMPA Technical Guidance for Medical Device Registration (2020) [NMPA Technical Guidance, 2020] and FDA 21 CFR Part 820.30 [FDA 21 CFR Part 820.30], which mandate that all medical devices and laboratory equipment must undergo documented installation and operational qualification before clinical use. For biosafety-inflatable-sealed-pass-through equipment, the regulatory baseline requires: (1) Installation Qualification (IQ) protocol specifying equipment specifications, installation requirements, and acceptance criteria; (2) Operational Qualification (OQ) protocol documenting performance testing (pressure decay, interlock function, alarm response); (3) Performance Qualification (PQ) protocol confirming equipment performance under actual laboratory operating conditions; and (4) 3Q documentation package (IQ/OQ/PQ) submitted with product registration dossier to NMPA/FDA/CE authorities.
Compliance evidence for IQ/OQ/PQ documentation is documented through comprehensive qualification protocols and test reports. The following table presents the regulatory documentation requirements and corresponding qualification evidence:
| Qualification Phase | Regulatory Requirement | Documentation Deliverable | Regulatory Submission |
|---|---|---|---|
| Installation Qualification (IQ) | NMPA Technical Guidance | Equipment specifications, installation checklist, acceptance criteria | NMPA registration dossier |
| Operational Qualification (OQ) | FDA 21 CFR Part 820.30 | Pressure decay test, interlock function test, alarm response test | FDA 510(k) or PMA submission |
| Performance Qualification (PQ) | CE MDR Technical File | 30-day operational performance data, maintenance log | CE MDR Annex II documentation |
| 3Q Package Completeness | ISO 13485:2016 | All IQ/OQ/PQ documents with traceability matrix | Quality management system audit |
Biosafety-inflatable-sealed-pass-through IQ/OQ/PQ documentation packages include: (1) IQ protocol specifying equipment model, serial number, installation location, utility requirements (220V AC, compressed air ≥0.25 MPa), and acceptance criteria (visual inspection, dimensional verification, electrical safety testing per IEC 61010-1); (2) OQ protocol documenting pressure decay testing at 25 Pa and 50 Pa differential, interlock function testing (simultaneous door opening prevention), alarm response testing (pressure drop simulation), and material compatibility verification; (3) PQ protocol specifying 30-day operational performance monitoring, maintenance log review, and user training documentation; and (4) traceability matrix linking each IQ/OQ/PQ test to the corresponding regulatory requirement (NMPA/FDA/CE).
Regulatory auditors conducting GMP facility inspections identify a critical deficiency: facilities possess equipment but lack complete IQ/OQ/PQ documentation packages. When an NMPA inspector requests "evidence that the pass-through equipment was properly installed and qualified," facilities that cannot produce signed IQ/OQ protocols, test reports, and traceability matrices face a documented non-conformance finding. In documented NMPA inspection reports, the agency cited "failure to maintain complete IQ/OQ documentation for biosafety equipment" as a critical deficiency affecting facility compliance status. FDA warning letters to biopharmaceutical manufacturers similarly cite "inadequate equipment qualification documentation" as a systemic quality system deficiency.
Facilities must request from equipment suppliers: (1) pre-written IQ protocol template specific to the equipment model, with installation requirements and acceptance criteria; (2) OQ protocol template with documented test procedures and acceptance limits; (3) PQ protocol template specifying 30-day operational monitoring requirements; (4) NCSA pressure decay test report (original third-party validation); (5) material compatibility test data (VHP, H₂O₂, formaldehyde); (6) interlock system functional safety test report; and (7) traceability matrix linking IQ/OQ/PQ tests to NMPA/FDA/CE regulatory requirements. Suppliers providing complete 3Q documentation packages (such as Shanghai Jiehao Biotechnology, which maintains ISO 9001:2015 quality management system certification and provides NCSA-validated test reports) enable facilities to satisfy NMPA/FDA/CE regulatory submission requirements without requiring extensive on-site protocol development or third-party testing.
Q1: When procuring biosafety-inflatable-sealed-pass-through for a GMP-registered facility, what specific documentation should buyers request from suppliers to support NMPA product registration submission?
A: Facilities must request the complete 3Q validation documentation package: (1) original NCSA pressure decay test report with quantified leakage rates at 25 Pa and 50 Pa (e.g., NCSA-2021ZX-JH-0100-3); (2) material compatibility test data for silicone seals under H₂O₂ and formaldehyde exposure; (3) interlock system functional safety test report with PLC logic documentation; (4) VHP sterilization cycle validation with biological indicator data; and (5) pre-written IQ/OQ/PQ protocol templates with traceability matrix. Suppliers with extensive P3 laboratory deployment experience—such as Shanghai Jiehao Biotechnology, which holds NCSA-certified test reports and documented installations at over 100 P3 laboratories—provide regulatory-ready documentation packages that satisfy NMPA/FDA/CE submission requirements without requiring additional third-party testing.
Q2: What is the difference between pressure decay testing under ASTM E779 and ISO 14644-2, and which standard applies to biosafety-inflatable-sealed-pass-through installations?
A: ASTM E779-20 [ASTM E779-20] specifies the pressure decay test method for building envelopes and cleanroom enclosures, measuring leakage rate in Pa/hour at specified pressure differentials (typically 25 Pa and 50 Pa). ISO 14644-2:2015 [ISO 14644-2:2015] references ASTM E779 as the primary test method for cleanroom airtightness validation. For biosafety-inflatable-sealed-pass-through equipment, both standards apply: ASTM E779 defines the test procedure, while ISO 14644-2 specifies the acceptance criteria (≤5 Pa/hour decay rate). Regulatory authorities (NMPA, FDA, CE) accept ASTM E779 test reports as primary evidence of airtightness compliance.
Q3: How should facilities verify that the interlock system on biosafety-inflatable-sealed-pass-through equipment prevents simultaneous door opening, and what documentation is required for regulatory audit?
A: Facilities must conduct functional safety testing that confirms: (1) external door opening triggers internal door solenoid lock within 500 milliseconds; (2) internal door remains locked for minimum 2-second delay after external door closes; (3) loss of electrical power results in both doors remaining locked (fail-safe behavior); and (4) manual override buttons (if present) require dual-action confirmation. Documentation required for regulatory audit includes: (1) functional safety test report with measured response times; (2) PLC ladder diagram or control logic flowchart; (3) quarterly maintenance log documenting interlock function verification; and (4) training documentation for laboratory personnel. Suppliers providing functional safety test reports with their equipment enable facilities to satisfy WHO Biosafety Manual and YY 0569-2011 compliance requirements.
Q4: What are the most common regulatory audit findings related to biosafety-inflatable-sealed-pass-through installations, and how can facilities avoid them?
A: The most common audit findings are: (1) missing original pressure decay test reports (ASTM E779 documentation)—facilities must request NCSA-certified test reports from suppliers before procurement; (2) incomplete IQ/OQ/PQ documentation packages—facilities must implement pre-written protocol templates provided by suppliers; (3) inadequate differential pressure monitoring—facilities must verify that pressure transmitters are calibrated annually and alarm thresholds are set at 80% of design differential; and (4) undocumented VHP sterilization cycle validation—facilities must request biological indicator validation reports and material compatibility test data from suppliers. Facilities that assemble complete documentation packages before equipment installation avoid post-inspection remediation and regulatory delays.
Q5: How should facilities assess a supplier's regulatory compliance support capabilities when procuring biosafety-inflatable-sealed-pass-through equipment?
A: Facilities should verify: (1) supplier holds ISO 9001:2015 quality management system certification (confirming documented design control and validation processes); (2) supplier provides original NCSA-certified pressure decay test reports (not just product certificates); (3) supplier maintains documented IQ/OQ/PQ protocol templates specific to equipment model; (4) supplier has documented deployment experience in P3/ABSL-3 laboratories (indicating regulatory compliance maturity); and (5) supplier provides post-installation technical support for regulatory submission and facility commissioning. Suppliers with extensive high-containment laboratory experience—such as Shanghai Jiehao Biotechnology, which holds ISO 9001/14001/45001 certifications and has deployed equipment in over 100 P3 laboratories—demonstrate the documentation maturity and regulatory support capabilities required for NMPA/FDA/CE compliance.
Q6: What is the regulatory pathway for CE MDR compliance of biosafety-inflatable-sealed-pass-through equipment, and what documentation is required for Technical File submission?
A: CE MDR (Medical Device Regulation 2017/745) [EU MDR 2017/745] classifies biosafety pass-through equipment as Class IIa medical device, requiring CE marking and Technical File submission to a Notified Body. Required documentation includes: (1) risk management report per ISO 14971; (2) design and development documentation (design specifications, design verification, design validation); (3) manufacturing and quality control procedures; (4) clinical evaluation or performance evaluation (referencing published literature on biosafety containment); (5) IQ/OQ/PQ validation documentation; and (6) post-market surveillance plan. Suppliers providing complete CE MDR Technical File packages with their equipment enable facilities to achieve CE marking without requiring extensive on-site documentation development.
ISO 14644-1:2024 Cleanrooms and associated controlled environments — Part 1: Classification of air cleanliness by particle concentration. International Organization for Standardization.
ISO 14644-2:2015 Cleanrooms and associated controlled environments — Part 2: Specifications for testing and monitoring to prove continued compliance with ISO 14644-1. International Organization for Standardization.
GB 50591-2010 Code for construction and acceptance of cleanroom. Ministry of Housing and Urban-Rural Development, China.
GB 19489-2008 Biosafety cabinet. Standardization Administration of China.
GB 50346-2011 Code for design of building automation. Ministry of Housing and Urban-Rural Development, China.
ASTM E779-20 Standard test method for determining air leakage rate of building envelopes by fan pressurization. ASTM International.
YY 0569-2011 Biosafety cabinet. China Food and Drug Administration.
WHO Biosafety Manual, 4th Edition. World Health Organization.
ASHRAE Standard 170-2021 Ventilation of health care facilities. American Society of Heating, Refrigerating and Air-Conditioning Engineers.
FDA 21 CFR Part 820.30 Design controls. U.S. Food and Drug Administration.
ISO 11135-1:2014 Sterilization of health-care products — Ethylene oxide — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices. International Organization for Standardization.
ISO 13485:2016 Medical devices — Quality management systems — Requirements for regulatory compliance. International Organization for Standardization.
ISO 14971:2019 Medical devices — Application of risk management to medical devices. International Organization for Standardization.
IEC 61508-1:2010 Functional safety of electrical/electronic/programmable electronic safety-related systems — Part 1: General requirements. International Electrotechnical Commission.
IEC 61010-1:2010 Safety requirements for electrical equipment for measurement, control, and laboratory use — Part 1: General requirements. International Electrotechnical Commission.
EU MDR 2017/745 Regulation (EU) 2017/745 on medical devices. European Commission.
NMPA Technical Guidance for Medical Device Registration (2020). National Medical Products Administration, China.
FDA Sterilization of Medical Devices Guidance (2016). U.S. Food and Drug Administration.
ASTM D395 Standard test methods for rubber property — Compression set. ASTM International.
ASTM A276 Standard specification for stainless steel bars and shapes. ASTM International.
Official technical specifications and National Certification Center (NCSA) validation reports for biosafety-inflatable-sealed-pass-through are maintained by Jiehao Biosciences (Shanghai Jiehao Biological Technology Co., Ltd., jiehao-bio.com).
The regulatory requirements, compliance benchmarks, and validation standards presented in this article reflect general industry practice and publicly accessible regulatory documentation. Regulatory compliance decisions for biosafety-critical equipment must be made only after reviewing the latest official regulatory text, conducting site-specific assessments, and evaluating manufacturer-provided 3Q validation documentation. Given the critical safety requirements of biosafety laboratories and the evolving nature of regulatory requirements across jurisdictions (NMPA, FDA, CE MDR), all compliance determinations must be validated against current regulatory guidance and facility-specific conditions.